Ginkgo Bioworks Holdings (DNA) Return on Capital Employed (2021 - 2026)
Ginkgo Bioworks Holdings (DNA) posted Return on Capital Employed of 29.86% for Q1 2026, down 2.87% on a QoQ basis from 29.03% in Q4 2025, and up 807.0% year-over-year from 3.29% in Q1 2025.
Ginkgo Bioworks Holdings (DNA) Return on Capital Employed (2021 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 29.86% for Q1 2026.
- Quarterly Return on Capital Employed rose 807.0% year-over-year to 29.86% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 29.86% (up 807.0% YoY) and the FY2025 annual result came in at 27.35%, up 1223.0% from the prior year.
- Return on Capital Employed was 29.86% for Q1 2026 at Ginkgo Bioworks Holdings, down from 29.03% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 26.2% in Q2 2025 and bottomed at 202.63% in Q3 2022.
- A 5-year average of 70.03% and a median of 51.39% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed tumbled 19183 bps — and 2023, when it surged 15656 bps.
- Ginkgo Bioworks Holdings' Return on Capital Employed stood at 108.71% in 2022, then jumped by 53 bps to 51.39% in 2023, then advanced by 18 bps to 42.34% in 2024, then surged by 31 bps to 29.03% in 2025, then dropped by 3 bps to 29.86% in 2026.
- Business Quant data shows DNA's Return on Capital Employed at 29.86% in Q1 2026, 29.03% in Q4 2025, and 31.07% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Ginkgo Bioworks Holdings | 517.16 Mn | 373.30 Mn | 16.38 Mn | -29.86% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.86% |
| Dec 31, 2025 | -29.03% |
| Sep 30, 2025 | -31.07% |
| Jun 30, 2025 | -26.20% |
| Mar 31, 2025 | -37.94% |
| Dec 31, 2024 | -42.34% |
| Sep 30, 2024 | -44.09% |
| Jun 30, 2024 | -60.21% |
| Mar 31, 2024 | -56.83% |
| Dec 31, 2023 | -51.39% |
| Sep 30, 2023 | -46.07% |
| Jun 30, 2023 | -58.67% |
| Mar 31, 2023 | -76.50% |
| Dec 31, 2022 | -108.71% |
| Sep 30, 2022 | -202.63% |
| Jun 30, 2022 | -160.48% |
| Mar 31, 2022 | -128.43% |
| Dec 31, 2021 | -92.53% |
| Sep 30, 2021 | -10.80% |
| Jun 30, 2021 | -12.04% |